Navigation Links
Major advances in breast, prostate, colorectal cancer featured at ASCO Annual Meeting
Date:6/2/2014

CHICAGO Findings from four phase III clinical trials in breast, prostate, and colorectal cancers were released today at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO). The studies were presented in ASCO's Plenary session, which features the meeting's most important clinical cancer research with the greatest potential to impact patient care.

These pivotal studies reveal new ways to optimize commonly used chemotherapy, hormone therapies, and newer targeted drugs, and answer critical questions about the comparative effectiveness of two common treatment regimens for advanced colorectal cancer. All four trials were supported, at least in part, with federal funding through the U.S. National Institutes of Health.

"Today's results answer critical questions faced by people with cancer and their doctors every day. There is no doubt that patients will live longer and better because of these studies," said Clifford A. Hudis, MD, FACP, president of ASCO and chief of the Breast Cancer Medicine Service at Memorial Sloan-Kettering Cancer Center. "These major advances and many others in the history of cancer research were only possible thanks to our nation's long-standing commitment to funding clinical cancer research. That commitment must be sustained."

The Plenary studies are:

Adjuvant exemestane is more effective than tamoxifen when combined with ovarian function suppression in young women with hormone-sensitive, early-stage breast cancer: Post-surgery (adjuvant) exemestane is more effective at preventing breast cancer recurrences than tamoxifen when given with ovarian function suppression in young women with hormone receptor-positive, early breast cancer, reducing the relative risk of developing a recurrent cancer by 28 percent.

Addition of docetaxel to initial hormone therapy substantially improves survival in men with metastatic, hormone-sensitive prostate cancer: The findings suggest inclusion of docetaxel in first-line therapies for men with advanced disease who are healthy enough for chemotherapy, especially those with extensive disease spread.

First-line bevacizumab plus chemotherapy and cetuximab plus chemotherapy provide similar survival benefit for patients with metastatic colorectal cancer: Large U.S.-funded head-to-head comparison trial answers a long-standing question about the relative effectiveness of four common regimens, offering patients and providers new reassurance as they face treatment decisions.

Adding lapatinib to adjuvant trastuzumab does not improve outcomes for women with early-stage HER2-positive breast cancer: Results from the phase III ALTTO study indicate that post-surgery treatment with the two anti-HER2 drugs does not improve disease-free survival compared to standard treatment with trastuzumab alone.


'/>"/>

Contact: Wendy Stokes
wendy.stokes@asco.org
312-949-3232
American Society of Clinical Oncology
Source:Eurekalert

Related medicine news :

1. Researchers address major geographic disparities in access to kidney transplantation
2. Major discovery on the mechanism of drug resistance in leukemia and other cancers
3. Major EPSRC Programme Grant to support new Oxford Centre for Drug Delivery Devices
4. Therapy sought to reduce major risk from minor bleeding that can follow stroke
5. Major lung resection safer than ever, especially at the busiest hospitals
6. Genetic alterations in shared biological pathways as major risk factor for ASD
7. Gen X obesity a major problem for healthcare, workforce
8. Surgery after major stroke also improves survival odds in elderly patients
9. A majority prefers letting computers decide
10. Major third-hand smoke compound causes DNA damage -- and potentially cancer
11. Patient requests for specific drugs have major impact on prescribing, reports study in Medical Care
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... (PRWEB) , ... January 19, 2017 , ... ... dynamic telemedicine solutions, has recently unveiled impressive transportable capabilities with their iMedHD2™ Portable ... product is an extension to RMT technology that delivers HD, dynamic, streaming ultrasound ...
(Date:1/19/2017)... ... 19, 2017 , ... WholeHealth is announcing their participation in ... Andrew Petersen and Trish Henrie-Barrus will be present Saturday and Sunday in the ... , “We know it’s easy to get carried away when you’re having ...
(Date:1/19/2017)... (PRWEB) , ... January 19, 2017 , ... ... dermatologist by the American Board of Dermatology and fellowship trained Mohs and cosmetic ... National Institutes of Health, Dr. Li completed his internship in internal medicine at ...
(Date:1/19/2017)... ... January 19, 2017 , ... Bio-Optronics Inc. is ... modern CTMS workflow designed to seamlessly integrate and streamline the way researchers prepare ... single page, maximizing usability and improving efficiency significantly for users – a first ...
(Date:1/19/2017)... ... 19, 2017 , ... Students interested in video can get a jump start ... will earn a $1,000 scholarship and have his or her video posted on the ... is May 31, with the winner announced on June 9. , The competition is ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... , January 19, 2017 ... appears serious about reducing the FDA,s regulatory strictness ... in the medical drug industry, many of the ... new clinical trials and development of advanced drug ... ahead with recent developments include:  Moleculin Biotech, Inc., ...
(Date:1/19/2017)... CLEVELAND , Jan. 18, 2017  ViewRay, ... the world,s first and only clinical MRI-guided radiation ... gross proceeds of approximately $26.1 million through a ... Puissance Capital Management led the financing and was ... OrbiMed Advisors, LLC and Kearny Venture Partners, and ...
(Date:1/19/2017)...   Synthetic Biologics, Inc. (NYSE MKT: ... to preserve the microbiome to protect and restore ... initiate a Phase 2b/3 adaptive pivotal trial for ... designed to reduce methane production by certain microorganisms ... treat the underlying cause of irritable bowel syndrome ...
Breaking Medicine Technology: